このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

上皮成長因子受容体(EGFR)エクソン20挿入またはその他の珍しい変異を伴う進行性非小細胞肺がん患者におけるジパレルチニブの研究。 (REZILIENT2)

2026年10月5日 更新者:Taiho Oncology, Inc.

エクソン20挿入および稀な/単一または複合上皮成長因子受容体変異を有する局所進行性または転移性非小細胞肺がん患者を対象としたジパレルチニブの安全性と有効性を評価する非盲検第2b相国際多施設コホート試験。

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts). The drug-drug interaction (DDI) substudy will assess the potential DDI effects of zipalertinib on the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates and transporter substrates and also evaluate the relationship between zipalertinib concentration and QT interval change from baseline. Additionally, dose optimization substudy will be conducted to confirm an optimized dose of zipalertinib monotherapy.

Participants will be enrolled into 1 of the 4 following cohorts:

  • Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately).
  • Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy.
  • Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD). Participants may or may not have had prior treatment for advanced disease.
  • Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.

For DDI substudy, participants will be enrolled in two groups:

  • CYP Cocktail Group will receive a single dose of cocktail of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
  • Transporter Cocktail Group will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

For dose-optimization substudy, participants with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor protein ex20ins mutations (EGFRmts) will be randomized to receive zipalertinib at different doses with continuous daily dosing until any discontinuation criterion is met. Participants will be enrolled into two groups: Arm A and Arm B, in which they will receive different doses of zipalertinib.

研究の種類

介入

入学 (推定)

220

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35294
        • 引きこもった
        • University of Alabama at Birmingham
    • California
      • Duarte、California、アメリカ、91010
        • 募集
        • City of Hope - Duarte
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Beth Israel Deaconess Medical Center
    • Nevada
      • Las Vegas、Nevada、アメリカ、89169
        • 募集
        • Comprehensive Cancer Centers of Nevada - Central Valley - Twain
    • New Jersey
      • Basking Ridge、New Jersey、アメリカ、07920
        • 募集
        • Memorial Sloan Kettering Cancer Center - Basking Ridge
      • Middletown、New Jersey、アメリカ、07748
        • 募集
        • Memorial Sloan Kettering Cancer Center - Monmouth
      • Montvale、New Jersey、アメリカ、07645
        • 募集
        • Memorial Sloan Kettering Cancer Center - Bergen
    • New York
      • Commack、New York、アメリカ、11725
        • 募集
        • Memorial Sloan Kettering Cancer Center - Commack
      • Harrison、New York、アメリカ、10604
        • 募集
        • Memorial Sloan Kettering Cancer Center - Westchester
      • Long Island City、New York、アメリカ、11101
        • 募集
        • MSK Cancer Center
      • Uniondale、New York、アメリカ、11553
        • 募集
        • Memorial Sloan Kettering Cancer Center - Nassau
    • Ohio
      • Canton、Ohio、アメリカ、44718
        • 募集
        • Gabrail Cancer and Research Center
      • Columbus、Ohio、アメリカ、43219
        • 引きこもった
        • Zangmeister Cancer Center
      • Toledo、Ohio、アメリカ、43623
        • 引きこもった
        • The Toledo Clinic Cancer Center
    • Tennessee
      • Nashville、Tennessee、アメリカ、37203
        • 引きこもった
        • SCRI Oncology Partners
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • University of Texas MD Anderson Cancer Center
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 募集
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • IDS Pharmacy
    • England
      • Barnet、England、イギリス、EN5 3DJ
        • 募集
        • The Royal Free Hospital NHS Foundation Trust
      • London、England、イギリス、NW3 2QG
        • 募集
        • Royal Free London NHS Foundation Trust
      • Manchester、England、イギリス、M20 4BX
        • 募集
        • The Christie NHS Foundation Trust
      • Nottingham、England、イギリス、NG5 1PB
        • 募集
        • Nottingham University Hospitals NHS Trust
      • Cremona、イタリア、26100
        • 募集
        • Azienda Socio-Sanitaria Territoriale di Cremona
      • Milan、イタリア、20132
        • 募集
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
      • Parma、イタリア、43126
        • 募集
        • Azienda Ospedaliero-Universitaria di Parma
      • Ravenna、イタリア、48121
        • 募集
        • Ospedale S. Maria delle Croci
    • Florence
      • Florence、Florence、イタリア、50134
        • 募集
        • Azienda Ospedaliero - Universitaria Careggi
    • Forli-Cesena
      • Meldola、Forli-Cesena、イタリア、47014
        • 募集
        • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
    • New South Wales
      • Bankstown、New South Wales、オーストラリア、2200
        • 募集
        • Bankstown-Lidcombe Hospital
      • Saint Leonards、New South Wales、オーストラリア、2065
        • 募集
        • Genesis Care North Shore
    • Western Australia
      • Joondalup、Western Australia、オーストラリア、6027
        • 引きこもった
        • Joondalup Hospital Pharmacy
      • Brampton、カナダ、L6R 3J7
        • 募集
        • William Osler Health System - Brampton Civic Hospital
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic de Barcelona
      • Barcelona、スペイン、08017
        • 募集
        • UOMi Clinica Mi Tres Torres
      • Barcelona、スペイン、08023
        • 募集
        • Hospital Quirónsalud Barcelona
      • Jaén、スペイン、23007
        • 募集
        • Complejo Hospitalario de Jaen
      • Madrid、スペイン、28041
        • 募集
        • Hospital Universitario 12 de Octubre
      • Madrid、スペイン、28040
        • 募集
        • Hospital Universitario Fundación Jiménez Díaz
      • Madrid、スペイン、28046
        • 募集
        • Hospital La Paz
      • Madrid、スペイン、28033
        • 募集
        • MD Anderson Cancer Center Madrid
    • Malaga
      • Málaga、Malaga、スペイン、29010
        • 募集
        • Hospital Regional Universitario de Málaga - Hospital General
      • Adana、トルコ(Türkiye)、01140
        • 募集
        • Medical Park Seyhan Hastanesi
      • Edirne、トルコ(Türkiye)、22030
        • 募集
        • Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi
      • Istanbul、トルコ(Türkiye)、34722
        • 募集
        • Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Istanbul、トルコ(Türkiye)、34214
        • 引きこもった
        • Bagcilar Medipol Mega Universite Hastanesi
    • Istanbul
      • Esenyurt、Istanbul、トルコ(Türkiye)、34517
        • 募集
        • Istinye Üniversite Hastanesi Liv Hospital Bahcesehir
      • Dresden、ドイツ、01307
        • 募集
        • Uniklinik Dresden
      • Giessen、ドイツ、35392
        • 募集
        • UKGM Studienzentrale
      • Regensburg、ドイツ、93053
        • 引きこもった
        • UKR Innere Med II Pneumologie
    • Hassen
      • Kassel、Hassen、ドイツ、34125
        • 募集
        • Gesundheit Nordhessen Holding AG
      • Saint-Herblain、フランス、44800
        • 募集
        • Hopital Nord Laennec
    • Aslace
      • Strasbourg、Aslace、フランス、67091
        • 引きこもった
        • Nouvel Hôpital Civil
    • Auvergne-Rhône-Alpes
      • Lyon、Auvergne-Rhône-Alpes、フランス、69008
        • 募集
        • Centre Leon Berard
    • Basse-Normandie
      • Caen、Basse-Normandie、フランス、14033
        • 募集
        • CHU Caen Normandie
    • Limousin
      • Limoges、Limousin、フランス、87042
        • 募集
        • Centre Hospitalier Universitaire Limoges
    • New Aquitaine
      • Pessac、New Aquitaine、フランス、33604
        • 募集
        • Hopital Haut Leveque
    • Provence-Alpes-Côte d'Azur Region
      • Marseille、Provence-Alpes-Côte d'Azur Region、フランス、13015
        • 募集
        • Hôpital Nord de Marseille
    • Île-de-France Region
      • Boulogne-Billancourt、Île-de-France Region、フランス、92100
        • 募集
        • Hopital Ambroise Pare
      • Paris、Île-de-France Region、フランス、75005
        • 募集
        • Institut Curie
      • Okayama、日本、700-8558
        • 募集
        • Okayama University Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、464-8681
        • 募集
        • Aichi Cancer Center
    • Chiba
      • Kashiwa-shi、Chiba、日本、277-8577
        • 募集
        • National Cancer Center Hospital East
    • Hukuoka
      • Fukuoka、Hukuoka、日本、811-1395
        • 募集
        • NHO Kyushu Cancer Center
    • Miyagi
      • Sendai、Miyagi、日本、980-0873
        • 募集
        • Sendai Kousei Hospital
    • Niigata
      • Niigata、Niigata、日本、951-8566
        • 募集
        • Niigata Cancer Center Hospital
    • Osaka
      • Sayama、Osaka、日本、589-8511
        • 募集
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun、Shizuoka、日本、411-8777
        • 募集
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo Ku、Tokyo、日本、104-0045
        • 募集
        • National Cancer Center Hospital
      • Koto-ku、Tokyo、日本、135-8550
        • 募集
        • Cancer Institute Hospital of JFCR
    • Gyeonggi-do
      • Goyang-si、Gyeonggi-do、韓国、10408
        • 引きこもった
        • National Cancer Center - Korea
      • Suwon、Gyeonggi-do、韓国、16499
        • 募集
        • Ajou University Hospital
      • Suwon、Gyeonggi-do、韓国、16247
        • 募集
        • Saint Vincent's Hospital
    • Gyeongsangnamdo [Kyongsangnam-do]
      • Jinju、Gyeongsangnamdo [Kyongsangnam-do]、韓国、52727
        • 募集
        • Gyeongsang National University Hospital
    • Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
      • Incheon、Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]、韓国、22332
        • 募集
        • Inha University Hospital
    • Jeollanam-do
      • Hwasun-gun、Jeollanam-do、韓国、58128
        • 引きこもった
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
      • Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韓国、05505
        • 募集
        • Asan Medical Center
      • Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韓国、08308
        • 募集
        • Korea University Guro Hospital
      • Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韓国、03080
        • 募集
        • Seoul National University Hospital
      • Soeul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韓国、06591
        • 引きこもった
        • Seoul St. Mary's Hospital
    • Hong Kong Island
      • Pok Fu Lam、Hong Kong Island、香港
        • 募集
        • Queen Mary Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Written informed consent.

  2. ≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.

  3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    Cohort A participants:

    • Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US).

    • Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

      i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor for eligibility assessment.

    • Participants with brain metastasis must be neurologically stable. Participants must have received central nervous system (CNS)-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening Period. Additionally, they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with a history of uncontrolled seizures or LMD are not eligible.

    Cohort B participants:

    • Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
    • Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.

    Cohort C participants:

    • Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).

    • Presence of brain metastasis(es) characterized as at least one of the following:

      • Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR
      • LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
    • Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.

    Cohort D participants:

    • Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
    • Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
    • Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
  4. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

  5. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.

  6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.

  7. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.

  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

  9. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.

DDI Substudy:

  1. Participant has pathologically confirmed, locally advanced or metastatic NSCLC:

    a. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory (outside of the US) local laboratory, defined as either one of the following EGFRmts:

    • ex20ins EGFRmt OR
    • other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR
    • common EGFRmt (eg, ex19del or L858R)
  2. Participant has progressed on or after receiving prior standard of care (SoC) systemic therapy for their locally advanced or metastatic NSCLC disease unless:

    • Participant for whom no approved therapy with demonstrated clinical benefit is indicated or available,
    • Participant is intolerant to the available first-line (1L) SoC treatment options, OR
    • Participant has refused 1L SoC treatment options (after being appropriately informed of the treatment options, risks, and benefits).
  3. Participants with brain metastasis are eligible if they fulfill all of the criteria below:

    • Have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI or CT scan) during the Screening Period,
    • Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment,
    • Are neurologically stable with no history of uncontrolled seizures.
  4. ECOG PS of 0 or 1.

Dose Optimization Substudy:

  1. Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    1. Documented EGFR ex20ins status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US)
    2. Progressed on or after systemic therapy standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

    Note: Progression on or after systemic therapy with amivantamab is permitted (eg, given as monotherapy or in combination with chemotherapy).

  2. Participants with CNS metastases are eligible if both of the following criteria are met:

    i. Measurable lesions according to RANO-BM defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 millimeters (mm), or at least 5 mm if MRI slice thickness is ≤ 1.5 mm ii. Previously received definitive local treatment and have stable CNS disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) OR Asymptomatic CNS metastases ≤ 2 cm in size if, in the opinion of the investigator, immediate definitive treatment is not indicated.

  3. Measurable disease per RECIST 1.1.

  4. Has archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers

  5. ECOG PS of 0 or 1.

  6. Has adequate organ function.

Exclusion Criteria:

  1. Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.

  2. Has received any of the following within the specific time frame specified:

    1. Participant has received Zipalertinib (TAS6417/CLN081) at any time
    2. CNS radiotherapy (gamma knife radiotherapy is allowed) ≤ 12 weeks, thoracic radiotherapy ≤ 28 days, or other palliative radiation ≤ 14 days prior to the first dose of study
    3. Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
    4. Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
    5. Any prior treatment with an EGFR exon20ins- targeted TKI
    6. Participants with leptomeningeal CNS disease.
  3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.

  4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.

  5. Impaired cardiac function or clinically significant cardiac disease including any of the following:

    1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification.
    2. Serious cardiac arrhythmias requiring treatment.
    3. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
  6. Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).

  7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

    1. Adequately treated basal or squamous cell carcinoma of the skin
    2. Cancer in situ of the breast or cervix
    3. Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
    4. Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment
  8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.

  9. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.

  10. Active bleeding disorders.

  11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.

  12. Is pregnant, lactating, or planning to become pregnant.

  13. The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A ("prior ex20ins treatment")

Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ
実験的:Cohort B ("first-line treatment")

Cohort B participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ
実験的:Cohort C ("active brain mets")

Cohort C participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ
実験的:Cohort D ("other uncommon EGFRmts").

Cohort D participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ
実験的:DDI Substudy: CYP Cocktail Group

Participants will receive a single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ

Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.

実験的:DDI Substudy: Transporter Cocktail Group

Participants will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ

Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

実験的:Dose Optimization Substudy: Arm A

Participants will receive zipalertinib, orally, at Arm A dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ
実験的:Dose Optimization Substudy: Arm B

Participants will receive zipalertinib, orally, at Arm B dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

他の名前:
  • CLN-081
  • ジパレルチニブ

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
コホート1-4:目的応答率(ORR)
時間枠:約2年まで
約2年まで
用量最適化サブスタディ:盲検化独立中央画像判定(BICR)による評価での全奏効率(ORR)
時間枠:最大約2年間
最大約2年間

二次結果の測定

結果測定
時間枠
コホート C: 頭蓋内 (i) 全奏効率 (iORR)
時間枠:最長約2年
最長約2年
コホートC:完全応答の頭蓋内期間(IDCR)
時間枠:約2年まで
約2年まで
コホートC:反応の頭蓋内期(IDOR)
時間枠:約2年まで
約2年まで
コホート1-4:治療のある参加者の数緊急有害事象(TEAE)の副イベントのための国立がん研究所共通用語基準バージョン5.0(CTCAE v5.0)に従って等級付け
時間枠:約2年まで
約2年まで
コホート1-4:臨床的実験室パラメーターに臨床的に有意な変化を持つ参加者の数
時間枠:約2年まで
約2年まで
コホート1-4:バイタルサインに臨床的に有意な変化を持つ参加者の数
時間枠:約2年まで
約2年まで
コホート1-4:心電図(ECG)パラメーターの臨床的に有意な変化を持つ参加者の数
時間枠:約2年まで
約2年まで
コホート1-4:左心室駆出率(LVEF)が変化した参加者の数(ECHO)およびマルチゲート取得(MUGA)スキャンを使用して評価された
時間枠:約2年まで
約2年まで
コホート1-4:疾病管理率(DCR)
時間枠:約2年まで
約2年まで
コホート1-4:応答期間(DOR)
時間枠:約2年まで
約2年まで
コホート1-4:無増悪生存(PFS)
時間枠:約2年まで
約2年まで
コホート1-4:全生存(OS)
時間枠:約2年まで
約2年まで
コホート1-4:Zipalertinibの最小血漿濃度(CMIN)
時間枠:約2年まで
約2年まで
DDI Sududy:CYPカクテルグループにおけるZipalertinib投与後のFridericiaの式(QTCF)間隔を使用して、心拍数を使用して心拍数を修正したQT間隔のベースラインからの変化
時間枠:サイクル1(サイクル長= 21日)
サイクル1(サイクル長= 21日)
DDI Sududy:CYPグループおよびトランスポーターカクテルグループにおけるZipalertinibの複数回投与後の幾何平均最大血漿濃度(CMAX)
時間枠:サイクル1(サイクル長= 21日)
サイクル1(サイクル長= 21日)
DDI Sududy:CYPグループおよびトランスポーターカクテルグループにおけるZipalertinibの複数の用量投与後の曲線下面積(AUC)
時間枠:サイクル1(サイクル長= 21日)
サイクル1(サイクル長= 21日)
DDI Sududy:CYPグループおよびトランスポーターカクテルの治療に敏感な有害事象(TEAE)を持つ参加者の数
時間枠:サイクル1(サイクル長= 21日)
サイクル1(サイクル長= 21日)
用量最適化サブスタディ:BICRおよび治験責任医師による評価による奏効持続期間(DoR)
時間枠:最長約2年
最長約2年
用量最適化サブスタディ:BICRおよび治験責任医師による評価に基づく奏効までの時間
時間枠:約2年間まで
約2年間まで
用量最適化サブスタディ:BICRおよび担当医師による評価に基づくベースラインからの腫瘍サイズの変化率
時間枠:約2年間まで
約2年間まで
用量最適化サブスタディ:BICRおよび担当医師による評価に基づくDCR
時間枠:最大約2年間
最大約2年間
用量最適化サブスタディ:BICRおよび治験責任医師による評価によるPFS
時間枠:最大約2年間
最大約2年間
用量最適化サブスタディ: 6カ月PFS率
時間枠:約2年間まで
約2年間まで
投与量最適化サブスタディ:研究者による評価に基づくORR
時間枠:約2年まで
約2年まで
用量最適化サブスタディ:全生存期間(OS)
時間枠:最大約2年間
最大約2年間
投与量最適化サブスタディ:神経腫瘍学脳転移評価基準(RANO-BM)に基づく頭蓋内客観的奏効率(iORR)
時間枠:最大約2年間
最大約2年間
用量最適化サブスタディ:頭蓋内反応持続期間(iDOR)
時間枠:約2年間まで
約2年間まで
投与量最適化サブスタディ:頭蓋内病変制御率(iDCR)
時間枠:最大約2年間
最大約2年間
用量最適化サブスタディ:有害事象(AE)および重篤な有害事象(SAE)を経験した参加者の数
時間枠:約2年まで
約2年まで

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年7月31日

一次修了 (推定)

2028年8月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2023年7月11日

QC基準を満たした最初の提出物

2023年7月21日

最初の投稿 (実際)

2023年8月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • TAS6417-201
  • 2023-503865-48 (EudraCT番号)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。